文献速递肿瘤 PET/CT

复发前列腺癌68Ga-PSMA-11 PET/CT改良协议与常规协议对比

68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-11-01

该回顾性研究比较了复发前列腺癌患者68Ga-PSMA-11 PET/CT常规协议(注射后1小时采集)与改良协议(注射后1.5小时采集、口服水化及注射呋塞米)的效果。共纳入2017年112例和2018年156例患者,结果显示改良协议肿瘤对比度和示踪剂摄取显著更高,膀胱平均SUVmean显著更低,病理扫描率有升高趋势但未达统计学显著。

要点

  • 改良协议(延迟采集+水化+呋塞米)使肿瘤对比度和示踪剂摄取显著提高(p<0.001)。
  • 改良协议膀胱平均SUVmean显著降低(p<0.001)。
  • 病理扫描率改良协议更高但差异无统计学意义,低PSA水平下可能更有优势。

核心结论

  • 改良协议(注射后1.5小时延迟采集联合水化及呋塞米)可获得更高的肿瘤对比度和示踪剂摄取,并可能提高病理扫描率,尤其在低PSA水平时。

研究设计与样本

  • 回顾性比较研究,纳入2017年常规协议112例和2018年改良协议156例复发前列腺癌患者的68Ga-PSMA-11 PET/CT扫描。

主要发现

  • 改良协议肿瘤对比度和示踪剂摄取均显著高于常规协议(p<0.001)。
  • 病理扫描率改良协议为76.3% vs 常规68.8%(所有PSA值),PSA<0.5 ng/ml时为38.9% vs 25.0%,PSA>0.5-≤2.0 ng/ml时为60.0% vs 56.7%,差异均无统计学意义。
  • 改良协议膀胱平均SUVmean显著低于常规协议(p<0.001)。

关键数值与推荐

  • 常规协议:注射后1小时采集,无进一步准备。
  • 改良协议:注射后1.5小时采集,注射后0.5小时口服水化1 L水,注射后1小时注射呋塞米20 mg。

临床怎么用

  • 对于复发前列腺癌的68Ga-PSMA-11 PET/CT,可考虑采用延迟至注射后1.5小时采集联合水化及呋塞米方案以提高肿瘤对比度并降低膀胱放射性。

局限性

  • 本研究为回顾性比较,两组为不同年份的历史队列,病理扫描率差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 68Ga-PSMA-11 PET/CT is commonly performed at 1 h post injection (p.i.). However, various publications have demonstrated that most prostate cancer (PC) lesions exhibit higher contrast at later imaging. The aim of this study was to compare the "common" protocol of 68Ga-PSMA-11 PET/CT with a modified protocol. METHODS: In 2017, we used the following scanning protocol for 68Ga-PSMA-11 PET/CT in patients with recurrent PC: acquisition at 1 h p.i. without further preparations. From 2018, all scans were conducted at 1.5 h p.i. In addition, patients were orally hydrated with 1 L of water 0.5 h p.i. and were injected with 20 mg of furosemide 1 h p.i. Both protocols including 112 patients (2017) and 156 (modified protocol in 2018) were retrospectively compared. Rates of pathologic scans, maximum standardized uptake values (SUVmax), and tumor contrast (ratio lesion-SUVmax/background-SUVmean) as well as average standardized uptake values (SUVmean) of urinary bladder were analyzed. RESULTS: Both tumor contrast and tracer uptake were significantly (p < 0.001) higher in the novel protocol. Although statistically not significant, the rates of pathologic scans were also higher in the modified protocol: 76.3% vs. 68.8% for all PSA values including 38.9% vs. 25.0% for PSA < 0.5 ng/ml and 60.0% vs. 56.7% for PSA > 0.5-≤ 2.0 ng/ml. Average SUVmean of the urinary bladder was significantly (p < 0.001) lower with the modified protocol. CONCLUSIONS: The modified protocol, which includes a combination of delayed image acquisition at 1.5 h p.i., hydration, and furosemide resulted in higher tumor contrast and seems to have the potential to increase the rates of pathological scans, especially at low PSA levels.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Haupt F, Dijkstra L, Alberts I, et al. 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. Eur J Nucl Med Mol Imaging. 2019. PMID: 31673789. doi:10.1007/s00259-019-04548-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。